Guide

Compounded GLP-1 Regulation: What Changed and What to Check

Compounded GLP-1 products sit inside a changing federal and state framework. The legal analysis depends on who compounds the drug, which ingredients are used, whether an approved product is in shortage, and what claims are made. This page organizes the public record. It does not provide purchasing guidance or decide whether a compounded product is appropriate for a reader.

Approved Products and Compounded Products Are Different Records

Ozempic and Wegovy contain semaglutide. Mounjaro and Zepbound contain tirzepatide. Each approved product went through FDA review for specific indications, labeling, manufacturing controls, and presentations. A compounded preparation is not an FDA-approved generic version and is not reviewed by the FDA for safety, effectiveness, or manufacturing quality before it reaches a patient.

Key points

• FDA approval attaches to a specific product, manufacturer, formulation, labeling, and indication.
• Compounded drugs can serve patient-specific needs under defined legal conditions, but they do not carry FDA approval.
• The name of the active ingredient alone does not establish equivalence between an approved product and a compounded preparation.
• Readers should separate claims about the approved molecule from claims about a specific compounded product or pharmacy.

The 503A and 503B Pathways

Section 503A generally covers patient-specific compounding by licensed pharmacists or physicians under state oversight, subject to federal conditions. Section 503B covers outsourcing facilities that register with the FDA and may compound larger batches under a different set of requirements. Registration as an outsourcing facility is not the same as FDA approval of every compounded product.

Key points

• 503A and 503B are separate statutory pathways with different conditions and oversight structures.
• State boards of pharmacy remain important for licensing and complaint records.
• 503B outsourcing facilities are subject to FDA inspection and current good manufacturing practice requirements.
• A telehealth brand, prescribing group, dispensing pharmacy, and outsourcing facility may be separate companies. Check each role.

Shortage Status Changes the Analysis

Federal law contains restrictions on compounding drugs that are essentially copies of commercially available products. Shortage status can affect how those restrictions apply, but it does not erase the remaining conditions for lawful compounding. Because shortage listings and enforcement policies can change, old social posts and landing pages are not reliable records of the current position.

Key points

• Check the current FDA shortage record instead of relying on an archived marketing claim.
• Shortage status is only one part of the legal framework.
• Claims that a compounded product is the same as, generic to, or FDA-approved like a branded product require careful scrutiny.
• Peptide Report links new FDA proposals, guidance, safety communications, and warning letters through Regulatory Watch.

A Practical Public-Record Checklist

A useful review starts by identifying every company in the path and checking the official records attached to each one. Marketing pages often compress several legal entities into one consumer-facing brand, which makes the underlying pharmacy and manufacturing relationships easy to miss.

Key points

• Identify the prescribing medical group, dispensing pharmacy, and any outsourcing facility.
• Check state licenses and the FDA outsourcing-facility record where applicable.
• Read the exact ingredient, concentration, labeling, storage, and adverse-event instructions supplied with the prescription.
• Check FDA safety communications and warning letters for the companies and claims involved.
• Treat price, availability, and outcome claims as separate from evidence about the approved drug.

Related pages